Equitable Holdings (EQH) Appoints Douglas Dachille to its Board

Equitable Holdings, Inc. (NYSE: EQH) today announced the appointment of Douglas Dachille as an independent member of its Board of Directors, effective immediately.

Mr. Dachille has amassed a distinguished career across three decades with proven expertise in the most strategic matters facing the insurance, banking and asset management industries. This includes leading complex corporate transactions, understanding capital markets and designing innovative investment solutions to meet insurance liabilities.

“On behalf of the Board of Directors, I am delighted to welcome Doug Dachille to Equitable Holdings,” said Joan Lamm-Tennant, Chair of the Equitable Holdings Board of Directors. “His experience leading insurance and asset management organizations will be instrumental as we continue to enhance the company’s value and navigate the evolving industry and macro-economic environment.”

Mr. Dachille served as Chief Investment Officer of American International Group Inc. (AIG) from 2015 until 2021, overseeing a $350 billion portfolio. During this time, he played a critical role stabilizing the company after the financial crisis and its subsequent financial recovery. Mr. Dachille joined AIG when it acquired First Principles Capital Management, an institutional fixed income asset manager, which he co-founded and led as Chief Executive Officer. Prior to co-founding First Principles, he was President and Chief Operating Officer of Zurich Capital Markets. Mr. Dachille began his career at JPMorgan Chase, where he held a variety of leadership roles including Global Head of Proprietary Trading and Co-Treasurer.

“Doug brings to us relevant experience across our integrated advice, retirement and asset management businesses,” said Mark Pearson, President and Chief Executive Officer of Equitable Holdings. “His unparalleled industry perspective will help guide us as we continue to deliver on our financial commitments, grow our businesses and create value for our shareholders.”

Mr. Dachille currently serves as an independent director of the BridgeBio Pharma, Inc. Board of Directors and previously served on the board of directors for Lyndra Therapeutics®. He earned a Bachelor of Science degree from Union University through a joint program with Albany Medical College, and later earned an MBA from the University of Chicago, where he was named a Pew Scholar.

You May Also Be Interested In

• EyePoint Pharmaceuticals (EYPT) call put ratio 1.4 calls to 1 put as share price up 8.9%
• Popular stocks with increasing option volume: INTC MU SPCX NFLX PLTR SNDK CRWV AVGO NKE WOLF MSTR
• Infleqtion opens new Colorado headquarters for quantum work